Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Design Consideration01:22

Design Consideration

586
Designing a structure involves a series of considerations, primarily the material's ultimate strength, calculated through tests that measure changes under increased force until the material reaches its breaking point or limit. The ultimate load, where the material breaks, is divided by its original cross-sectional area, resulting in the ultimate normal stress or strength. The ultimate shearing stress is another significant factor taken into account.
The factor of safety is another key...
586
Tensile Strength Considerations of Concrete01:16

Tensile Strength Considerations of Concrete

561
Considering the tensile strength of concrete involves recognizing that the theoretical strength of cement paste can be up to a thousand times higher than what is observed in practical applications. This significant discrepancy is largely attributed to the presence of microscopic cracks within the concrete. These cracks tend to amplify stress at their tips when a load is applied, a phenomenon explained by Griffith's theory of brittle fracture.
The dimensions and shape of a concrete specimen...
561
Transmission Line Design Considerations01:23

Transmission Line Design Considerations

634
Aluminum has become the material of choice for overhead transmission lines, surpassing copper due to its abundance and cost-effectiveness. The most prevalent type is the aluminum conductor, steel-reinforced (ACSR), which combines aluminum strands around a steel core. Other variants include all-aluminum conductors (AAC), all-aluminum alloy conductors (AAAC), aluminum conductor alloy-reinforced (ACAR), and aluminum-clad steel conductors. Advanced designs, such as aluminum conductors with steel...
634
Gene Therapy00:59

Gene Therapy

27.7K
Gene therapy is a technique where a gene is inserted into a person’s cells to prevent or treat a serious disease. The added gene may be a healthy version of the gene that is mutated in the patient, or it could be a different gene that inactivates or compensates for the patient’s disease-causing gene. For example, in patients with severe combined immunodeficiency (SCID) due to a mutation in the gene for the enzyme adenosine deaminase, a functioning version of the gene can be...
27.7K
What is Natural Selection?01:32

What is Natural Selection?

129.8K
Natural selection is an evolutionary process in which individuals with survival-promoting traits reproduce at higher rates. These favorable traits become more common within a population or species. Naturally selected traits initially arise via random genetic mutations. In order for selection to occur, there must be variation within a population, the trait controlling the variation must be heritable, and there must be an evolutionary advantage for variation in the trait.
129.8K
Special considerations while measuring pulse01:13

Special considerations while measuring pulse

986
Assessing a patient's pulse is a fundamental skill in healthcare, but certain situations require special attention:
986

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Advances in Hemophilia: From Joint Health to FVIII Guidelines and the Clinical Integration of Rebalancing Agents.

American journal of hematology·2026
Same author

The WFH Guidelines for the Management of Haemophilia: AAV Gene Therapy, 2025.

Haemophilia : the official journal of the World Federation of Hemophilia·2025
Same author

Characterization of the clinical and laboratory phenotype of hemophilia carriers and trends of utilization of hemostatic therapies: analysis of the American Thrombosis and Hemostasis Network dataset.

Research and practice in thrombosis and haemostasis·2025
Same author

Gene therapy for hemophilia B: results from the phase 1/2 101HEMB01/02 studies.

Blood advances·2025
Same author

Corticosteroid use to mitigate transaminitis-associated decline in FVIII levels following valoctocogene roxaparvovec gene therapy: clinical practice guidance.

Journal of thrombosis and haemostasis : JTH·2025
Same author

Transitioning from emicizumab prophylaxis to valoctocogene roxaparvovec gene therapy: A simulation study for individuals with severe haemophilia A.

Haemophilia : the official journal of the World Federation of Hemophilia·2024

Related Experiment Video

Updated: Feb 13, 2026

Therapy Interventions for Upper Limb Amputees Undergoing Selective Nerve Transfers
07:59

Therapy Interventions for Upper Limb Amputees Undergoing Selective Nerve Transfers

Published on: October 29, 2021

4.2K

Consideration in hemophilia therapy selection.

Steven Pipe1

  • 1Hemophilia and Coagulation Disorders Program, University of Michigan, Ann Arbor, MI 48109, USA. ummdswp@med.umich.edu

Seminars in Hematology
|April 25, 2006
PubMed
Summary
This summary is machine-generated.

Advances in clotting factor therapies have reduced pathogen transmission risks. However, emerging infectious agents necessitate ongoing vigilance and patient-provider discussions regarding therapy selection.

More Related Videos

Tail Vein Transection Bleeding Model in Fully Anesthetized Hemophilia A Mice
08:13

Tail Vein Transection Bleeding Model in Fully Anesthetized Hemophilia A Mice

Published on: September 30, 2021

7.6K
Proton Therapy Delivery and Its Clinical Application in Select Solid Tumor Malignancies
08:34

Proton Therapy Delivery and Its Clinical Application in Select Solid Tumor Malignancies

Published on: February 6, 2019

21.1K

Related Experiment Videos

Last Updated: Feb 13, 2026

Therapy Interventions for Upper Limb Amputees Undergoing Selective Nerve Transfers
07:59

Therapy Interventions for Upper Limb Amputees Undergoing Selective Nerve Transfers

Published on: October 29, 2021

4.2K
Tail Vein Transection Bleeding Model in Fully Anesthetized Hemophilia A Mice
08:13

Tail Vein Transection Bleeding Model in Fully Anesthetized Hemophilia A Mice

Published on: September 30, 2021

7.6K
Proton Therapy Delivery and Its Clinical Application in Select Solid Tumor Malignancies
08:34

Proton Therapy Delivery and Its Clinical Application in Select Solid Tumor Malignancies

Published on: February 6, 2019

21.1K

Area of Science:

  • Hematology
  • Infectious Diseases
  • Biotechnology

Background:

  • Clotting factor therapies for hemophilia have evolved significantly.
  • Pathogen screening and inactivation methods have improved, reducing risks.
  • Recombinant clotting factors have largely replaced plasma-derived products.

Purpose of the Study:

  • To review the historical context of pathogen transmission in clotting factor therapies.
  • To highlight ongoing concerns regarding emerging infectious agents.
  • To emphasize the importance of informed therapy selection for hemophilia patients.

Main Methods:

  • Literature review of pathogen safety in clotting factor therapies.
  • Analysis of historical trends in hemophilia treatment and viral transmission.
  • Discussion of current vulnerabilities in plasma-derived and recombinant therapies.

Main Results:

  • Significant reduction in human immunodeficiency virus (HIV) and hepatitis C virus (HCV) transmission.
  • Introduction of recombinant factor VIII (FVIII) in 1992 marked a turning point.
  • Persistent concerns due to plasma components in some manufacturing processes.

Conclusions:

  • Healthcare providers must stay informed about emerging pathogens.
  • Proactive education and risk discussion with patients are crucial.
  • Informed therapy selection is essential for hemophilia patient safety.